GlassScriptPhysician profile
David I Cabral
NPI 1407031420
$2,669.12
in general payments reported to CMS, 2019-2025
32 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $651 · 2021: $456 · 2022: $311 · 2023: $303 · 2024: $215 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $738.38 | 2019-2022 | |
| Novo Nordisk INC | $239.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $204.86 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $151.54 | 2022-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $139.71 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $126.98 | 2019-2020 | |
| Exact Sciences Corporation | $117.93 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $101.15 | 2022-2025 | |
| Amgen INC. | $88.39 | 2019-2025 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $82.31 | 2019-2021 | |
| Abbvie INC. | $80.18 | 2021-2023 | Ubrelvy |
| Pfizer INC. | $79.84 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $51.84 | 2025 | Keveyis |
| Avanir Pharmaceuticals, INC. | $49.56 | 2019-2020 | |
| Almatica Pharma LLC | $45.12 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.29 | 2020-2021 | |
| Lilly USA, LLC | $33.47 | 2020-2025 | Jardiance |
| Shield Therapeutics INC | $28.60 | 2023-2024 | Accrufer |
| Novartis Pharmaceuticals Corporation | $27.61 | 2019-2023 | |
| Sanofi Pasteur INC. | $25.68 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $23.60 | 2020 | |
| Seqirus USA INC | $21.78 | 2024 | Fluad, Flucelvax |
| Alvogen INC | $20.55 | 2025 | Teriparatide |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.37 | 2022 | |
| Glaxosmithkline, LLC. | $19.40 | 2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.68 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.97 | 2024 | Voquezna |
| Astellas Pharma US INC | $16.77 | 2023 | Veozah |
| Boston Scientific Corporation | $15.21 | 2019 | |
| Zyla Life Sciences, INC. | $15.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.23 | 2021 | |
| Nevro Corp. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cabral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.